Apitope Announces Positive Results with Novel Treatment for Graves’ Disease

HASSELT, Belgium and CHEPSTOW, WalesApril 16, 2018 /PRNewswire/ —

Phase I data show early efficacy in the majority of patients and a very favourable safety profile

Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment of Graves’ disease.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...